Remdesivir Medicine Comprehensive Study by Application (Ebola Virus Disease, Marburg Virus Infection, Possible COVID-19 Treatment), Administration (Oral, Intravenous), End-users (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Online Channel, Offline Channel) Players and Region - Global Market Outlook to 2026

Remdesivir Medicine Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Remdesivir Medicine Market Overview:
Remdesivir medicine is an anti-viral medication being studied as a possible post-infection treatment for COVID-19 illness. This medicine is a nucleotide analog, specifically an adenosine analog, which inserts into viral RNA chains causing their premature termination. It was developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections. It is an investigational antiviral compound undergoing clinical trials in China, the United States and the United Kingdom as a potential treatment for COVID-19. It is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.

Growth Drivers
  • Increased Prevalence of COVID-19 Illness
  • Highly Effective Anti-viral Medicine

Roadblocks
  • Lack of Clinical Evidence for COVID-19 Treatment

Opportunities
  • Increasing Number of Patients affecting COVID-19
  • Growth in the Healthcare Industry

Challenges
  • Stringent Government Rules and Regulations


Competitive Landscape:

Some of the key players profiled in the report are Gilead Sciences, Inc. (United States), Hainan Haiyao Co., Ltd. (China), Sanofi S.A. (France), GlaxoSmithKline plc (United Kingdom) and Cipla (India). Analyst at AMA Research see Global Players to retain maximum share of Global Remdesivir Medicine market by 2026. Considering Market by Administration, the sub-segment i.e. Oral will boost the Remdesivir Medicine market. Considering Market by End-users, the sub-segment i.e. Hospitals will boost the Remdesivir Medicine market. Considering Market by Distribution Channel, the sub-segment i.e. Online Channel will boost the Remdesivir Medicine market.

On 3 April, the European Medicines Agency (EMA) backed remdesivir for compassionate use for Covid-19 patients. One day later, Gilead noted it had reduced remdesivir’s manufacturing timeline from one year to around six months. Remdisivir was also cleared by the FDA for emergency use on 20 March, but new applications were suspended as of 23 March after a flood of requests.

What Can be Explored with the Remdesivir Medicine Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Remdesivir Medicine Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Remdesivir Medicine
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Remdesivir Medicine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Remdesivir Medicine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Remdesivir Medicine Manufacturers, Raw Material Suppliers, Distributors, Government Bodies and End-users.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Ebola Virus Disease
  • Marburg Virus Infection
  • Possible COVID-19 Treatment
By Administration
  • Oral
  • Intravenous

By End-users
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others

By Distribution Channel
  • Online Channel
  • Offline Channel

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of COVID-19 Illness
      • 3.2.2. Highly Effective Anti-viral Medicine
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. High Demand for Coronavirus Disease Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Remdesivir Medicine, by Application, Administration, End-users, Distribution Channel and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Remdesivir Medicine (Value)
      • 5.2.1. Global Remdesivir Medicine by: Application (Value)
        • 5.2.1.1. Ebola Virus Disease
        • 5.2.1.2. Marburg Virus Infection
        • 5.2.1.3. Possible COVID-19 Treatment
      • 5.2.2. Global Remdesivir Medicine by: Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Intravenous
      • 5.2.3. Global Remdesivir Medicine by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Ambulatory Surgical Centers
        • 5.2.3.4. Others
      • 5.2.4. Global Remdesivir Medicine by: Distribution Channel (Value)
        • 5.2.4.1. Online Channel
        • 5.2.4.2. Offline Channel
      • 5.2.5. Global Remdesivir Medicine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Remdesivir Medicine (Volume)
      • 5.3.1. Global Remdesivir Medicine by: Application (Volume)
        • 5.3.1.1. Ebola Virus Disease
        • 5.3.1.2. Marburg Virus Infection
        • 5.3.1.3. Possible COVID-19 Treatment
      • 5.3.2. Global Remdesivir Medicine by: Administration (Volume)
        • 5.3.2.1. Oral
        • 5.3.2.2. Intravenous
      • 5.3.3. Global Remdesivir Medicine by: End-users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Ambulatory Surgical Centers
        • 5.3.3.4. Others
      • 5.3.4. Global Remdesivir Medicine by: Distribution Channel (Volume)
        • 5.3.4.1. Online Channel
        • 5.3.4.2. Offline Channel
      • 5.3.5. Global Remdesivir Medicine Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Remdesivir Medicine (Price)
  • 6. Remdesivir Medicine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Gilead Sciences, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hainan Haiyao Co., Ltd. (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi S.A. (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cipla (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Global Remdesivir Medicine Sale, by Application, Administration, End-users, Distribution Channel and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Remdesivir Medicine (Value)
      • 7.2.1. Global Remdesivir Medicine by: Application (Value)
        • 7.2.1.1. Ebola Virus Disease
        • 7.2.1.2. Marburg Virus Infection
        • 7.2.1.3. Possible COVID-19 Treatment
      • 7.2.2. Global Remdesivir Medicine by: Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Intravenous
      • 7.2.3. Global Remdesivir Medicine by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Ambulatory Surgical Centers
        • 7.2.3.4. Others
      • 7.2.4. Global Remdesivir Medicine by: Distribution Channel (Value)
        • 7.2.4.1. Online Channel
        • 7.2.4.2. Offline Channel
      • 7.2.5. Global Remdesivir Medicine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Remdesivir Medicine (Volume)
      • 7.3.1. Global Remdesivir Medicine by: Application (Volume)
        • 7.3.1.1. Ebola Virus Disease
        • 7.3.1.2. Marburg Virus Infection
        • 7.3.1.3. Possible COVID-19 Treatment
      • 7.3.2. Global Remdesivir Medicine by: Administration (Volume)
        • 7.3.2.1. Oral
        • 7.3.2.2. Intravenous
      • 7.3.3. Global Remdesivir Medicine by: End-users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Ambulatory Surgical Centers
        • 7.3.3.4. Others
      • 7.3.4. Global Remdesivir Medicine by: Distribution Channel (Volume)
        • 7.3.4.1. Online Channel
        • 7.3.4.2. Offline Channel
      • 7.3.5. Global Remdesivir Medicine Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Remdesivir Medicine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Remdesivir Medicine: by Application(USD Million)
  • Table 2. Remdesivir Medicine Ebola Virus Disease , by Region USD Million (2015-2020)
  • Table 3. Remdesivir Medicine Marburg Virus Infection , by Region USD Million (2015-2020)
  • Table 4. Remdesivir Medicine Possible COVID-19 Treatment , by Region USD Million (2015-2020)
  • Table 5. Remdesivir Medicine: by Administration(USD Million)
  • Table 6. Remdesivir Medicine Oral , by Region USD Million (2015-2020)
  • Table 7. Remdesivir Medicine Intravenous , by Region USD Million (2015-2020)
  • Table 8. Remdesivir Medicine: by End-users(USD Million)
  • Table 9. Remdesivir Medicine Hospitals , by Region USD Million (2015-2020)
  • Table 10. Remdesivir Medicine Clinics , by Region USD Million (2015-2020)
  • Table 11. Remdesivir Medicine Ambulatory Surgical Centers , by Region USD Million (2015-2020)
  • Table 12. Remdesivir Medicine Others , by Region USD Million (2015-2020)
  • Table 13. Remdesivir Medicine: by Distribution Channel(USD Million)
  • Table 14. Remdesivir Medicine Online Channel , by Region USD Million (2015-2020)
  • Table 15. Remdesivir Medicine Offline Channel , by Region USD Million (2015-2020)
  • Table 16. South America Remdesivir Medicine, by Country USD Million (2015-2020)
  • Table 17. South America Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 18. South America Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 19. South America Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 20. South America Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 21. Brazil Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 22. Brazil Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 23. Brazil Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 24. Brazil Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 25. Argentina Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 26. Argentina Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 27. Argentina Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 28. Argentina Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 29. Rest of South America Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 30. Rest of South America Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 31. Rest of South America Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 32. Rest of South America Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 33. Asia Pacific Remdesivir Medicine, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 35. Asia Pacific Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 36. Asia Pacific Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 37. Asia Pacific Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 38. China Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 39. China Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 40. China Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 41. China Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 42. Japan Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 43. Japan Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 44. Japan Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 45. Japan Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 46. India Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 47. India Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 48. India Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 49. India Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 50. South Korea Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 51. South Korea Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 52. South Korea Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 53. South Korea Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 54. Taiwan Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 55. Taiwan Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 56. Taiwan Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 57. Taiwan Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 58. Australia Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 59. Australia Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 60. Australia Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 61. Australia Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 66. Europe Remdesivir Medicine, by Country USD Million (2015-2020)
  • Table 67. Europe Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 68. Europe Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 69. Europe Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 70. Europe Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 71. Germany Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 72. Germany Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 73. Germany Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 74. Germany Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 75. France Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 76. France Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 77. France Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 78. France Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 79. Italy Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 80. Italy Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 81. Italy Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 82. Italy Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 83. United Kingdom Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 84. United Kingdom Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 85. United Kingdom Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 86. United Kingdom Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 87. Netherlands Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 88. Netherlands Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 89. Netherlands Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 90. Netherlands Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 91. Rest of Europe Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 92. Rest of Europe Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 93. Rest of Europe Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 94. Rest of Europe Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 95. MEA Remdesivir Medicine, by Country USD Million (2015-2020)
  • Table 96. MEA Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 97. MEA Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 98. MEA Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 99. MEA Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 100. Middle East Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 101. Middle East Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 102. Middle East Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 103. Middle East Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 104. Africa Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 105. Africa Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 106. Africa Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 107. Africa Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 108. North America Remdesivir Medicine, by Country USD Million (2015-2020)
  • Table 109. North America Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 110. North America Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 111. North America Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 112. North America Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 113. United States Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 114. United States Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 115. United States Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 116. United States Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 117. Canada Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 118. Canada Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 119. Canada Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 120. Canada Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 121. Mexico Remdesivir Medicine, by Application USD Million (2015-2020)
  • Table 122. Mexico Remdesivir Medicine, by Administration USD Million (2015-2020)
  • Table 123. Mexico Remdesivir Medicine, by End-users USD Million (2015-2020)
  • Table 124. Mexico Remdesivir Medicine, by Distribution Channel USD Million (2015-2020)
  • Table 125. Remdesivir Medicine Sales: by Application(K Units)
  • Table 126. Remdesivir Medicine Sales Ebola Virus Disease , by Region K Units (2015-2020)
  • Table 127. Remdesivir Medicine Sales Marburg Virus Infection , by Region K Units (2015-2020)
  • Table 128. Remdesivir Medicine Sales Possible COVID-19 Treatment , by Region K Units (2015-2020)
  • Table 129. Remdesivir Medicine Sales: by Administration(K Units)
  • Table 130. Remdesivir Medicine Sales Oral , by Region K Units (2015-2020)
  • Table 131. Remdesivir Medicine Sales Intravenous , by Region K Units (2015-2020)
  • Table 132. Remdesivir Medicine Sales: by End-users(K Units)
  • Table 133. Remdesivir Medicine Sales Hospitals , by Region K Units (2015-2020)
  • Table 134. Remdesivir Medicine Sales Clinics , by Region K Units (2015-2020)
  • Table 135. Remdesivir Medicine Sales Ambulatory Surgical Centers , by Region K Units (2015-2020)
  • Table 136. Remdesivir Medicine Sales Others , by Region K Units (2015-2020)
  • Table 137. Remdesivir Medicine Sales: by Distribution Channel(K Units)
  • Table 138. Remdesivir Medicine Sales Online Channel , by Region K Units (2015-2020)
  • Table 139. Remdesivir Medicine Sales Offline Channel , by Region K Units (2015-2020)
  • Table 140. South America Remdesivir Medicine Sales, by Country K Units (2015-2020)
  • Table 141. South America Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 142. South America Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 143. South America Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 144. South America Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 145. Brazil Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 146. Brazil Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 147. Brazil Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 148. Brazil Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 149. Argentina Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 150. Argentina Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 151. Argentina Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 152. Argentina Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 153. Rest of South America Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 154. Rest of South America Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 155. Rest of South America Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 156. Rest of South America Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 157. Asia Pacific Remdesivir Medicine Sales, by Country K Units (2015-2020)
  • Table 158. Asia Pacific Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 159. Asia Pacific Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 160. Asia Pacific Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 161. Asia Pacific Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 162. China Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 163. China Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 164. China Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 165. China Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 166. Japan Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 167. Japan Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 168. Japan Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 169. Japan Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 170. India Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 171. India Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 172. India Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 173. India Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 174. South Korea Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 175. South Korea Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 176. South Korea Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 177. South Korea Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 178. Taiwan Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 179. Taiwan Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 180. Taiwan Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 181. Taiwan Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 182. Australia Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 183. Australia Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 184. Australia Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 185. Australia Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 186. Rest of Asia-Pacific Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 187. Rest of Asia-Pacific Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 188. Rest of Asia-Pacific Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 189. Rest of Asia-Pacific Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 190. Europe Remdesivir Medicine Sales, by Country K Units (2015-2020)
  • Table 191. Europe Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 192. Europe Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 193. Europe Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 194. Europe Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 195. Germany Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 196. Germany Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 197. Germany Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 198. Germany Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 199. France Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 200. France Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 201. France Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 202. France Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 203. Italy Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 204. Italy Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 205. Italy Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 206. Italy Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 207. United Kingdom Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 208. United Kingdom Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 209. United Kingdom Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 210. United Kingdom Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 211. Netherlands Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 212. Netherlands Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 213. Netherlands Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 214. Netherlands Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 215. Rest of Europe Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 216. Rest of Europe Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 217. Rest of Europe Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 218. Rest of Europe Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 219. MEA Remdesivir Medicine Sales, by Country K Units (2015-2020)
  • Table 220. MEA Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 221. MEA Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 222. MEA Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 223. MEA Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 224. Middle East Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 225. Middle East Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 226. Middle East Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 227. Middle East Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 228. Africa Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 229. Africa Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 230. Africa Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 231. Africa Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 232. North America Remdesivir Medicine Sales, by Country K Units (2015-2020)
  • Table 233. North America Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 234. North America Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 235. North America Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 236. North America Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 237. United States Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 238. United States Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 239. United States Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 240. United States Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 241. Canada Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 242. Canada Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 243. Canada Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 244. Canada Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 245. Mexico Remdesivir Medicine Sales, by Application K Units (2015-2020)
  • Table 246. Mexico Remdesivir Medicine Sales, by Administration K Units (2015-2020)
  • Table 247. Mexico Remdesivir Medicine Sales, by End-users K Units (2015-2020)
  • Table 248. Mexico Remdesivir Medicine Sales, by Distribution Channel K Units (2015-2020)
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Remdesivir Medicine: by Application(USD Million)
  • Table 255. Remdesivir Medicine Ebola Virus Disease , by Region USD Million (2021-2026)
  • Table 256. Remdesivir Medicine Marburg Virus Infection , by Region USD Million (2021-2026)
  • Table 257. Remdesivir Medicine Possible COVID-19 Treatment , by Region USD Million (2021-2026)
  • Table 258. Remdesivir Medicine: by Administration(USD Million)
  • Table 259. Remdesivir Medicine Oral , by Region USD Million (2021-2026)
  • Table 260. Remdesivir Medicine Intravenous , by Region USD Million (2021-2026)
  • Table 261. Remdesivir Medicine: by End-users(USD Million)
  • Table 262. Remdesivir Medicine Hospitals , by Region USD Million (2021-2026)
  • Table 263. Remdesivir Medicine Clinics , by Region USD Million (2021-2026)
  • Table 264. Remdesivir Medicine Ambulatory Surgical Centers , by Region USD Million (2021-2026)
  • Table 265. Remdesivir Medicine Others , by Region USD Million (2021-2026)
  • Table 266. Remdesivir Medicine: by Distribution Channel(USD Million)
  • Table 267. Remdesivir Medicine Online Channel , by Region USD Million (2021-2026)
  • Table 268. Remdesivir Medicine Offline Channel , by Region USD Million (2021-2026)
  • Table 269. South America Remdesivir Medicine, by Country USD Million (2021-2026)
  • Table 270. South America Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 271. South America Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 272. South America Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 273. South America Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 274. Brazil Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 275. Brazil Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 276. Brazil Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 277. Brazil Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 278. Argentina Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 279. Argentina Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 280. Argentina Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 281. Argentina Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 282. Rest of South America Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 283. Rest of South America Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 284. Rest of South America Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 285. Rest of South America Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 286. Asia Pacific Remdesivir Medicine, by Country USD Million (2021-2026)
  • Table 287. Asia Pacific Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 288. Asia Pacific Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 289. Asia Pacific Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 290. Asia Pacific Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 291. China Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 292. China Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 293. China Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 294. China Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 295. Japan Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 296. Japan Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 297. Japan Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 298. Japan Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 299. India Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 300. India Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 301. India Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 302. India Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 303. South Korea Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 304. South Korea Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 305. South Korea Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 306. South Korea Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 307. Taiwan Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 308. Taiwan Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 309. Taiwan Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 310. Taiwan Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 311. Australia Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 312. Australia Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 313. Australia Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 314. Australia Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 315. Rest of Asia-Pacific Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 316. Rest of Asia-Pacific Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 317. Rest of Asia-Pacific Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 318. Rest of Asia-Pacific Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 319. Europe Remdesivir Medicine, by Country USD Million (2021-2026)
  • Table 320. Europe Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 321. Europe Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 322. Europe Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 323. Europe Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 324. Germany Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 325. Germany Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 326. Germany Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 327. Germany Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 328. France Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 329. France Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 330. France Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 331. France Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 332. Italy Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 333. Italy Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 334. Italy Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 335. Italy Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 336. United Kingdom Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 337. United Kingdom Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 338. United Kingdom Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 339. United Kingdom Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 340. Netherlands Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 341. Netherlands Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 342. Netherlands Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 343. Netherlands Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 344. Rest of Europe Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 345. Rest of Europe Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 346. Rest of Europe Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 347. Rest of Europe Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 348. MEA Remdesivir Medicine, by Country USD Million (2021-2026)
  • Table 349. MEA Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 350. MEA Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 351. MEA Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 352. MEA Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 353. Middle East Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 354. Middle East Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 355. Middle East Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 356. Middle East Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 357. Africa Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 358. Africa Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 359. Africa Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 360. Africa Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 361. North America Remdesivir Medicine, by Country USD Million (2021-2026)
  • Table 362. North America Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 363. North America Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 364. North America Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 365. North America Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 366. United States Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 367. United States Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 368. United States Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 369. United States Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 370. Canada Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 371. Canada Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 372. Canada Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 373. Canada Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 374. Mexico Remdesivir Medicine, by Application USD Million (2021-2026)
  • Table 375. Mexico Remdesivir Medicine, by Administration USD Million (2021-2026)
  • Table 376. Mexico Remdesivir Medicine, by End-users USD Million (2021-2026)
  • Table 377. Mexico Remdesivir Medicine, by Distribution Channel USD Million (2021-2026)
  • Table 378. Remdesivir Medicine Sales: by Application(K Units)
  • Table 379. Remdesivir Medicine Sales Ebola Virus Disease , by Region K Units (2021-2026)
  • Table 380. Remdesivir Medicine Sales Marburg Virus Infection , by Region K Units (2021-2026)
  • Table 381. Remdesivir Medicine Sales Possible COVID-19 Treatment , by Region K Units (2021-2026)
  • Table 382. Remdesivir Medicine Sales: by Administration(K Units)
  • Table 383. Remdesivir Medicine Sales Oral , by Region K Units (2021-2026)
  • Table 384. Remdesivir Medicine Sales Intravenous , by Region K Units (2021-2026)
  • Table 385. Remdesivir Medicine Sales: by End-users(K Units)
  • Table 386. Remdesivir Medicine Sales Hospitals , by Region K Units (2021-2026)
  • Table 387. Remdesivir Medicine Sales Clinics , by Region K Units (2021-2026)
  • Table 388. Remdesivir Medicine Sales Ambulatory Surgical Centers , by Region K Units (2021-2026)
  • Table 389. Remdesivir Medicine Sales Others , by Region K Units (2021-2026)
  • Table 390. Remdesivir Medicine Sales: by Distribution Channel(K Units)
  • Table 391. Remdesivir Medicine Sales Online Channel , by Region K Units (2021-2026)
  • Table 392. Remdesivir Medicine Sales Offline Channel , by Region K Units (2021-2026)
  • Table 393. South America Remdesivir Medicine Sales, by Country K Units (2021-2026)
  • Table 394. South America Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 395. South America Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 396. South America Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 397. South America Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 398. Brazil Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 399. Brazil Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 400. Brazil Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 401. Brazil Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 402. Argentina Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 403. Argentina Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 404. Argentina Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 405. Argentina Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 406. Rest of South America Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 407. Rest of South America Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 408. Rest of South America Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 409. Rest of South America Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 410. Asia Pacific Remdesivir Medicine Sales, by Country K Units (2021-2026)
  • Table 411. Asia Pacific Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 412. Asia Pacific Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 413. Asia Pacific Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 414. Asia Pacific Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 415. China Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 416. China Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 417. China Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 418. China Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 419. Japan Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 420. Japan Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 421. Japan Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 422. Japan Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 423. India Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 424. India Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 425. India Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 426. India Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 427. South Korea Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 428. South Korea Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 429. South Korea Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 430. South Korea Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 431. Taiwan Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 432. Taiwan Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 433. Taiwan Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 434. Taiwan Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 435. Australia Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 436. Australia Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 437. Australia Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 438. Australia Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 439. Rest of Asia-Pacific Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 440. Rest of Asia-Pacific Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 441. Rest of Asia-Pacific Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 442. Rest of Asia-Pacific Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 443. Europe Remdesivir Medicine Sales, by Country K Units (2021-2026)
  • Table 444. Europe Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 445. Europe Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 446. Europe Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 447. Europe Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 448. Germany Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 449. Germany Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 450. Germany Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 451. Germany Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 452. France Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 453. France Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 454. France Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 455. France Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 456. Italy Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 457. Italy Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 458. Italy Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 459. Italy Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 460. United Kingdom Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 461. United Kingdom Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 462. United Kingdom Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 463. United Kingdom Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 464. Netherlands Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 465. Netherlands Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 466. Netherlands Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 467. Netherlands Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 468. Rest of Europe Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 469. Rest of Europe Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 470. Rest of Europe Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 471. Rest of Europe Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 472. MEA Remdesivir Medicine Sales, by Country K Units (2021-2026)
  • Table 473. MEA Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 474. MEA Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 475. MEA Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 476. MEA Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 477. Middle East Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 478. Middle East Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 479. Middle East Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 480. Middle East Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 481. Africa Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 482. Africa Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 483. Africa Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 484. Africa Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 485. North America Remdesivir Medicine Sales, by Country K Units (2021-2026)
  • Table 486. North America Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 487. North America Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 488. North America Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 489. North America Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 490. United States Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 491. United States Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 492. United States Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 493. United States Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 494. Canada Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 495. Canada Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 496. Canada Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 497. Canada Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 498. Mexico Remdesivir Medicine Sales, by Application K Units (2021-2026)
  • Table 499. Mexico Remdesivir Medicine Sales, by Administration K Units (2021-2026)
  • Table 500. Mexico Remdesivir Medicine Sales, by End-users K Units (2021-2026)
  • Table 501. Mexico Remdesivir Medicine Sales, by Distribution Channel K Units (2021-2026)
  • Table 502. Research Programs/Design for This Report
  • Table 503. Key Data Information from Secondary Sources
  • Table 504. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Remdesivir Medicine: by Application USD Million (2015-2020)
  • Figure 5. Global Remdesivir Medicine: by Administration USD Million (2015-2020)
  • Figure 6. Global Remdesivir Medicine: by End-users USD Million (2015-2020)
  • Figure 7. Global Remdesivir Medicine: by Distribution Channel USD Million (2015-2020)
  • Figure 8. South America Remdesivir Medicine Share (%), by Country
  • Figure 9. Asia Pacific Remdesivir Medicine Share (%), by Country
  • Figure 10. Europe Remdesivir Medicine Share (%), by Country
  • Figure 11. MEA Remdesivir Medicine Share (%), by Country
  • Figure 12. North America Remdesivir Medicine Share (%), by Country
  • Figure 13. Global Remdesivir Medicine: by Application K Units (2015-2020)
  • Figure 14. Global Remdesivir Medicine: by Administration K Units (2015-2020)
  • Figure 15. Global Remdesivir Medicine: by End-users K Units (2015-2020)
  • Figure 16. Global Remdesivir Medicine: by Distribution Channel K Units (2015-2020)
  • Figure 17. South America Remdesivir Medicine Share (%), by Country
  • Figure 18. Asia Pacific Remdesivir Medicine Share (%), by Country
  • Figure 19. Europe Remdesivir Medicine Share (%), by Country
  • Figure 20. MEA Remdesivir Medicine Share (%), by Country
  • Figure 21. North America Remdesivir Medicine Share (%), by Country
  • Figure 22. Global Remdesivir Medicine share by Players 2020 (%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Gilead Sciences, Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Hainan Haiyao Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 27. Hainan Haiyao Co., Ltd. (China) Revenue: by Geography 2020
  • Figure 28. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 30. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 32. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 33. Cipla (India) Revenue: by Geography 2020
  • Figure 34. Global Remdesivir Medicine: by Application USD Million (2021-2026)
  • Figure 35. Global Remdesivir Medicine: by Administration USD Million (2021-2026)
  • Figure 36. Global Remdesivir Medicine: by End-users USD Million (2021-2026)
  • Figure 37. Global Remdesivir Medicine: by Distribution Channel USD Million (2021-2026)
  • Figure 38. South America Remdesivir Medicine Share (%), by Country
  • Figure 39. Asia Pacific Remdesivir Medicine Share (%), by Country
  • Figure 40. Europe Remdesivir Medicine Share (%), by Country
  • Figure 41. MEA Remdesivir Medicine Share (%), by Country
  • Figure 42. North America Remdesivir Medicine Share (%), by Country
  • Figure 43. Global Remdesivir Medicine: by Application K Units (2021-2026)
  • Figure 44. Global Remdesivir Medicine: by Administration K Units (2021-2026)
  • Figure 45. Global Remdesivir Medicine: by End-users K Units (2021-2026)
  • Figure 46. Global Remdesivir Medicine: by Distribution Channel K Units (2021-2026)
  • Figure 47. South America Remdesivir Medicine Share (%), by Country
  • Figure 48. Asia Pacific Remdesivir Medicine Share (%), by Country
  • Figure 49. Europe Remdesivir Medicine Share (%), by Country
  • Figure 50. MEA Remdesivir Medicine Share (%), by Country
  • Figure 51. North America Remdesivir Medicine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Gilead Sciences, Inc. (United States)
  • Hainan Haiyao Co., Ltd. (China)
  • Sanofi S.A. (France)
  • GlaxoSmithKline plc (United Kingdom)
  • Cipla (India)
Select User Access Type

Key Highlights of Report


Oct 2021 209 Pages 65 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Remdesivir Medicine market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Remdesivir Medicine market are Gilead Sciences, Inc. (United States), Hainan Haiyao Co., Ltd. (China), Sanofi S.A. (France), GlaxoSmithKline plc (United Kingdom) and Cipla (India), to name a few.
"High Demand for Coronavirus Disease Treatment" is seen as one of major influencing trends for Remdesivir Medicine Market during projected period 2020-2026.

Know More About Global Remdesivir Medicine Market Report?